Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective lowered by Bank of America from $14.00 to $12.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price target indicates a potential upside of 128.57% from the company’s current price.

YMAB has been the subject of a number of other reports. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.30.

Y-mAbs Therapeutics Trading Up 8.2 %

Shares of YMAB opened at $5.25 on Wednesday. The company has a market cap of $235.14 million, a price-to-earnings ratio of -9.72 and a beta of 0.65. The business’s fifty day simple moving average is $6.39 and its two-hundred day simple moving average is $10.58. Y-mAbs Therapeutics has a 12 month low of $4.25 and a 12 month high of $18.17.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $26.70 million. During the same period last year, the business earned ($0.02) earnings per share. As a group, research analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the period. Barclays PLC raised its stake in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after acquiring an additional 56,244 shares during the period. Geode Capital Management LLC lifted its holdings in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics in the third quarter worth approximately $133,000. Finally, Caligan Partners LP increased its stake in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.